

# John R White

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8616400/publications.pdf>

Version: 2024-02-01

29  
papers

5,064  
citations

471509

17  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4861  
citing authors

#	ARTICLE	IF	CITATIONS
1	A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. <i>Nature</i> , 1994, 372, 739-746.	27.8	3,244
2	Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration. <i>Journal of Biological Chemistry</i> , 1998, 273, 10095-10098.	3.4	373
3	Glycan Array Screening Reveals a Candidate Ligand for Siglec-8*. <i>Journal of Biological Chemistry</i> , 2005, 280, 4307-4312.	3.4	242
4	A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit. <i>Journal of Immunology</i> , 2002, 169, 6435-6444.	0.8	153
5	Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 1093-1100.	2.9	151
6	Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. <i>Journal of Leukocyte Biology</i> , 1997, 62, 667-675.	3.3	144
7	Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration. <i>Journal of Biological Chemistry</i> , 2000, 275, 36626-36631.	3.4	103
8	Ligand-induced Desensitization of the Human CXC Chemokine Receptor-2 Is Modulated by Multiple Serine Residues in the Carboxyl-terminal Domain of the Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 8207-8214.	3.4	101
9	Cloning, in Vitro Expression, and Functional Characterization of a Novel Human CC Chemokine of the Monocyte Chemotactic Protein (MCP) Family (MCP-4) That Binds and Signals through the CC Chemokine Receptor 2B. <i>Journal of Biological Chemistry</i> , 1997, 272, 16404-16413.	3.4	84
10	Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. <i>Inflammation</i> , 1993, 17, 333-344.	3.8	81
11	Evaluation of Potent and Selective Small-Molecule Antagonists for the CXCR2 Chemokine Receptor. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1319-1321.	6.4	79
12	CK $\beta$ -8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. <i>Journal of Cellular Physiology</i> , 2000, 183, 196-207.	4.1	64
13	Identification of Unique Truncated KC/GRO $\beta$ Chemokines with Potent Hematopoietic and Anti-Infective Activities. <i>Journal of Immunology</i> , 2000, 164, 3774-3782.	0.8	52
14	Activation of Basophils and Mast Cells for Mediator Release. <i>International Archives of Allergy and Immunology</i> , 1987, 82, 327-332.	2.1	38
15	Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1445-1450.	2.2	34
16	Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1441-1444.	2.2	21
17	Best practices in bioassay development to support registration of biopharmaceuticals. <i>BioTechniques</i> , 2019, 67, 126-137.	1.8	20
18	Differential inhibition of histamine release from mast cells by protein kinase C inhibitors: Staurosporine and K-252a. <i>Biochemical Pharmacology</i> , 1990, 40, 447-456.	4.4	17

#	ARTICLE	IF	CITATIONS
19	Selective binding of the truncated form of the chemokine CXCR1 (25-99) to CC chemokine receptor 1 (CCR1). <i>Biochemical Pharmacology</i> , 2000, 59, 591-596.	4.4	15
20	[1] C <sub>1</sub> -X <sub>1</sub> -C chemokine receptor desensitization mediated through ligand-enhanced receptor phosphorylation on serine residues. <i>Methods in Enzymology</i> , 1997, 288, 3-15.	1.0	11
21	Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates. <i>PLoS ONE</i> , 2020, 15, e0231655.	2.5	11
22	Biotherapeutic Antibody Subunit LC-MS and Peptide Mapping LC-MS Measurements to Study Possible Biotransformation and Critical Quality Attributes In Vivo. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1415-1422.	3.3	8
23	Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 402-404.	2.5	7
24	Design and evaluation of small peptides mapping the exposed surface of IL-8. <i>International Journal of Peptide and Protein Research</i> , 1996, 47, 214-218.	0.1	5
25	The role of the anionic groups in the receptor binding of interleukin-8 antagonists. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 235-239.	0.1	3
26	Structure and Functional Characterization of a Humanized Anti-CCL20 Antibody following Exposure to Serum Reveals the Formation of Immune Complex That Leads to Toxicity. <i>Journal of Immunology</i> , 2021, 206, 1067-1076.	0.8	2
27	Pharmacological evaluation of leukotriene biosynthesis and inflammation in an adoptive model of peritoneal anaphylaxis in the mouse. <i>Drug Development Research</i> , 1993, 30, 83-90.	2.9	1
28	Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P. <i>Journal of Biological Chemistry</i> , 2021, 297, 101136.	3.4	0
29	A novel method for removing polyethyleneimine from biopharmaceutical samples: improving assay sensitivity of residual DNA qPCR. <i>BioTechniques</i> , 2020, 68, 353-358.	1.8	0